Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Cash Flow (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Net Cash Flow for 6 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 99.02% to $3.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$378.3 million, a 191.95% decrease, with the full-year FY2025 number at -$378.3 million, down 191.95% from a year prior.
  • Net Cash Flow was $3.9 million for Q4 2025 at Janux Therapeutics, up from -$4.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $403.9 million in Q4 2024 to a low of -$356.9 million in Q1 2025.
  • A 5-year average of $2.3 million and a median of $2.7 million in 2022 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 18917.56% in 2021, then surged 19571.26% in 2024.
  • Janux Therapeutics' Net Cash Flow stood at -$3.0 million in 2021, then tumbled by 345.54% to -$13.3 million in 2022, then skyrocketed by 115.41% to $2.1 million in 2023, then soared by 19571.26% to $403.9 million in 2024, then tumbled by 99.02% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Net Cash Flow are $3.9 million (Q4 2025), -$4.1 million (Q3 2025), and -$21.3 million (Q2 2025).